If biomarkers and adherence are optimal, consider whether an alternative GLP-1 formulation (oral semaglutide, tirzepatide, or dual-compound protocols like GLP-Squared) might better suit your physiology
Storing semaglutide at room temperature or warmer temperatures can degrade the active peptide, reducing its effectiveness for weight loss and metabolic control
Doubling up can lead to serious side effects like severe nausea, vomiting, or low blood sugar (hypoglycemia)
Protocols circulating in bodybuilding communities and some telehealth contexts lack prospective safety monitoring, pharmacovigilance, or ethics-committee oversight
A non-head-to-head comparison of outcomes (SURMOUNT-1 versus STEP-1): tirzepatide 15 mg produced an average of 20.9% weight loss at 72 weeks in SURMOUNT-1 (n=2,539)
Table 1: Adverse Reactions Occurring 5% in Pooled Clinical Studies up to 28 Weeks Duration in Adults with Type 1 Diabetes Table 2: Adverse Reactions Occurring 5% in Pooled Clinical Studies up to 1 Year Duration in Adults with Type 2 Diabetes Table 3: Adverse Reactions Occurring 10% in a 5-Year Study of Adults with Type 2 Diabetes Table 4: Adverse Reactions Occurring 5% in a 28-Week Clinical Study in Pediatric Patients with Type 1 Diabetes Severe Hypoglycemia Hypoglycemia was the most commonly observed adverse reaction in patients treated with insulin glargine
